MA45517B1 - Molécules de liaison inhibant la croissance de cancer - Google Patents

Molécules de liaison inhibant la croissance de cancer

Info

Publication number
MA45517B1
MA45517B1 MA45517A MA45517A MA45517B1 MA 45517 B1 MA45517 B1 MA 45517B1 MA 45517 A MA45517 A MA 45517A MA 45517 A MA45517 A MA 45517A MA 45517 B1 MA45517 B1 MA 45517B1
Authority
MA
Morocco
Prior art keywords
binding molecules
growth inhibitor
cancer growth
membrane
inhibitor binding
Prior art date
Application number
MA45517A
Other languages
English (en)
Other versions
MA45517A (fr
Inventor
Mark Throsby
Ton Logtenberg
Johannes Carolus Clevers
Robert Gerhardus Jacob Vries
Eduard Batlle
Bram Herpers
Original Assignee
Merus Nv
Koninklijke Nederlandse Akademie Van Wetenschappen
Ocello B V
Inst Catalana Recerca Estudis Avancats
Fundacio Inst De Recerca Biomedica Irb Barcelona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv, Koninklijke Nederlandse Akademie Van Wetenschappen, Ocello B V, Inst Catalana Recerca Estudis Avancats, Fundacio Inst De Recerca Biomedica Irb Barcelona filed Critical Merus Nv
Publication of MA45517A publication Critical patent/MA45517A/fr
Publication of MA45517B1 publication Critical patent/MA45517B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des moyens et des procédés pour inhiber la croissance d'un cancer. Les moyens, dans certains modes de réalisation, comprennent des protéines et des anticorps qui se lient à une partie extracellulaire d'un membre de la famille du récepteur du facteur de croissance épidermique (egf) associé à la membrane et à une partie extracellulaire d'un élément d'une voie de signalisation wnt associé à la membrane. L'invention concerne en outre diverses cellules et tests qui sont utiles pour produire des protéines, des anticorps et des cellules.
MA45517A 2015-10-23 2016-10-21 Molécules de liaison inhibant la croissance de cancer MA45517B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15191343 2015-10-23
EP16168647 2016-05-06
PCT/NL2016/050726 WO2017069628A2 (fr) 2015-10-23 2016-10-21 Molécules de liaison inhibant la croissance de cancer

Publications (2)

Publication Number Publication Date
MA45517A MA45517A (fr) 2018-08-29
MA45517B1 true MA45517B1 (fr) 2021-04-30

Family

ID=57190021

Family Applications (2)

Application Number Title Priority Date Filing Date
MA054760A MA54760A (fr) 2015-10-23 2016-10-21 Molécules de liaison qui inhibent la croissance d'un cancer
MA45517A MA45517B1 (fr) 2015-10-23 2016-10-21 Molécules de liaison inhibant la croissance de cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA054760A MA54760A (fr) 2015-10-23 2016-10-21 Molécules de liaison qui inhibent la croissance d'un cancer

Country Status (26)

Country Link
US (2) US11939394B2 (fr)
EP (2) EP3912998A3 (fr)
JP (3) JP7296728B2 (fr)
KR (1) KR20180100305A (fr)
CN (2) CN108602888B (fr)
AU (2) AU2016340764B2 (fr)
BR (1) BR112018008068A2 (fr)
CA (1) CA3002957A1 (fr)
CY (1) CY1124108T1 (fr)
DK (1) DK3365373T3 (fr)
EA (1) EA201890866A1 (fr)
ES (1) ES2865482T3 (fr)
HK (1) HK1253914A1 (fr)
HR (1) HRP20210483T1 (fr)
HU (1) HUE055222T2 (fr)
LT (1) LT3365373T (fr)
MA (2) MA54760A (fr)
MD (1) MD3365373T2 (fr)
MX (2) MX2018004988A (fr)
NZ (1) NZ742290A (fr)
PL (1) PL3365373T3 (fr)
RS (1) RS61800B1 (fr)
SG (1) SG11201803359VA (fr)
SI (1) SI3365373T1 (fr)
WO (1) WO2017069628A2 (fr)
ZA (1) ZA201802758B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6771385B2 (ja) 2014-02-28 2020-10-21 メルス ナムローゼ フェンノートシャップ 二重特異性抗体および医薬組成物
MX2016012873A (es) * 2014-04-04 2017-03-07 Bionomics Inc Anticuerpos humanizados que se unen al receptor 5 acoplado a proteina g que contiene repeticion rica en leucina (lgr5).
SI3365373T1 (sl) 2015-10-23 2021-08-31 Merus N.V. Vezne molekule, ki zaviranjo rast raka
US10745487B2 (en) 2016-03-22 2020-08-18 Bionomics Limited Method of treating cancer by administering an anti-LGR5 monoclonal antibody
WO2018132572A1 (fr) * 2017-01-11 2018-07-19 The Board Of Trustees Of The Leland Stanford Junior University Molécules de substitution de r-spondine (rspo)
AU2018211985A1 (en) * 2017-01-26 2019-07-18 Surrozen Operating, Inc. Tissue-specific Wnt signal enhancing molecules and uses thereof
MX2019011660A (es) 2017-03-31 2019-11-18 Merus Nv Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1).
IL271833B2 (en) * 2017-07-06 2024-09-01 Merus Nv Antibodies that regulate biological activity expressed by a cell
WO2019009727A1 (fr) 2017-07-06 2019-01-10 Merus N.V. Anticorps bispécifiques anti-pd1 anti-tim3
KR20200042485A (ko) 2017-08-09 2020-04-23 메뤼스 엔.페. EGFR 및 cMET에 결합하는 항체
AR115320A1 (es) * 2018-03-30 2020-12-23 Merus Nv Anticuerpo multivalente
JP2021530223A (ja) * 2018-07-09 2021-11-11 スロゼン， インコーポレイテッド 組織特異性Ｗｎｔシグナル増強分子及びその使用
AU2019416324A1 (en) * 2018-12-27 2021-07-22 H. Lee Moffitt Cancer Center And Research Institute Inc. Bispecific antibody for membrane clearance of target receptors
CN113439089A (zh) 2018-12-31 2021-09-24 美勒斯公司 截短的多价多元体
CA3124768A1 (fr) * 2018-12-31 2020-07-09 Merus N.V. Domaines de liaison mixtes
CN114426578A (zh) * 2019-02-14 2022-05-03 美勒斯公司 结合egfr、her2及her3的结合部分的组合
BR112021016149A2 (pt) 2019-02-26 2021-10-13 Janssen Biotech, Inc. Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met
TW202102544A (zh) * 2019-04-04 2021-01-16 日商小野藥品工業股份有限公司 雙特異性抗體
WO2020230091A1 (fr) 2019-05-14 2020-11-19 Janssen Biotech, Inc. Polythérapies avec des anticorps anti-egfr/c-met bispécifiques et des inhibiteurs de tyrosine kinase egfr de troisième génération
EP4017879A2 (fr) * 2019-08-19 2022-06-29 Merus N.V. Traitement du cancer avec une combinaison d'un anticorps se liant à lgr5 et egfr et d'un inhibiteur de la topoisomérase de type i
US20240026031A1 (en) * 2019-11-01 2024-01-25 The Regents Of The University Of California Degradation of surface proteins using bispecific binding agent
EP4114854A1 (fr) * 2020-03-05 2023-01-11 UMC Utrecht Holding B.V. Ubiquitine ligases membranaires pour cibler la dégradation de protéines
EP4139357A1 (fr) 2020-04-24 2023-03-01 Merus N.V. Traitement de cancers avec un anticorps se liant à lgr5 et egfr
AU2021291235A1 (en) * 2020-06-18 2022-12-22 Umc Utrecht Holding B.V. Screening method for effective target - E3 ligase combinations
CN118717980A (zh) * 2020-09-08 2024-10-01 复旦大学 ASGR1作为药物靶点在治疗SARS-CoV-2感染中的应用
WO2022131912A1 (fr) 2020-12-15 2022-06-23 Merus N.V. Traitement de cancers avec un anticorps se liant au lgr5 et au egfr
WO2022131918A1 (fr) 2020-12-18 2022-06-23 Merus N.V. Composition d'anticorps
CN114853889B (zh) * 2021-02-03 2024-03-01 中国科学院动物研究所 针对人gpr48的单克隆抗体及其应用
CN113307882B (zh) * 2021-05-12 2022-12-20 东北大学 靶向治疗Rspo过度激活导致的结直肠癌的融合蛋白SZ1及其偶联纳米药物
MX2024004113A (es) 2021-10-06 2024-04-19 Merus Nv Tratamiento de canceres tratados con inhibidores de punto de control inmunitarios con alta expresion del receptor del factor de crecimiento epidermico (egfr) mediante el uso de un anticuerpo que se une al menos al receptor del factor de crecimiento epidermico (egfr).
WO2024136658A1 (fr) 2022-12-23 2024-06-27 Merus N.V. Traitement combiné de cancers à l'aide d'un anticorps qui se lie au moins à egfr et à un inhibiteur de point de contrôle immunitaire
WO2024144401A1 (fr) 2022-12-28 2024-07-04 Merus N.V. Traitement du cancer avec une combinaison d'un anticorps qui se lie à l'egfr et de médicaments cytotoxiques
CN116082510B (zh) * 2023-03-07 2023-12-05 四川尚锐生物医药有限公司 一种单克隆抗体或其抗原结合片段及其抗肿瘤的用途

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
FI884924A (fi) 1987-10-28 1989-04-29 Oncogen Humanimmuglobulin som producerats med hybrid-dna-teknik.
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
ES2199216T3 (es) 1991-07-15 2004-02-16 The Wellcome Foundation Limited Produccion de anticuerpos.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE29706518U1 (de) 1997-04-11 1997-05-22 E. Missel GmbH & Co., 70374 Stuttgart Trägersystem für Bade-, Dusch- oder Whirlwannen
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
IL132560A0 (en) 1997-05-02 2001-03-19 Genentech Inc A method for making multispecific antibodies having heteromultimeric and common components
PT1161548E (pt) 1999-04-15 2005-06-30 Crucell Holland Bv Producao de proteinas recombinantes numa celula humana utilizando sequencias codificando a proteina e1 de adenovirus
DE29915950U1 (de) 1999-09-10 1999-12-30 CMW Automation GmbH, 65594 Runkel Vorrichtung zum Elektrolytbefüllen der Zellen eines Akkumulators
US20070111201A1 (en) 2001-04-30 2007-05-17 Benjamin Doranz Reverse transfection of cell arrays for structural and functional analyses of proteins
ES2344070T3 (es) 2001-07-04 2010-08-17 Chromagenics B.V. Secuencias de adn con actividad anti-represora.
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US20050130224A1 (en) 2002-05-31 2005-06-16 Celestar Lexico- Sciences, Inc. Interaction predicting device
CA2965865C (fr) 2002-07-18 2021-10-19 Merus N.V. Production par recombinaison de melanges d'anticorps
MXPA05006724A (es) 2003-01-07 2005-09-08 Symphogen As Metodo para producir proteinas policlonales recombinantes.
AU2004251890B2 (en) 2003-06-25 2010-09-23 Crucell Holland B.V. Binding molecules for the treatment of myeloid cell malignancies
SG155883A1 (en) 2004-06-03 2009-10-29 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
MX2007002856A (es) 2004-09-02 2007-09-25 Genentech Inc Metodos para el uso de ligandos receptores de muerte y anticuerpos c20.
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2599606A1 (fr) 2005-02-23 2006-08-31 Merrimack Pharmaceuticals, Inc. Agents de liaison bispecifiques utilises pour moduler une activite biologique
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
EP3050963B1 (fr) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Procédé pour la production de polypeptide au moyen de la régulation d'un ensemble
JP5474531B2 (ja) 2006-03-24 2014-04-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 操作されたヘテロ二量体タンパク質ドメイン
EP2035456A1 (fr) 2006-06-22 2009-03-18 Novo Nordisk A/S Production d'anticorps bispécifiques
WO2008027236A2 (fr) 2006-08-30 2008-03-06 Genentech, Inc. Anticorps multispécifiques
US8290739B2 (en) 2006-10-20 2012-10-16 Amfit, Inc. Method for determining relative mobility of regions of an object
WO2008140493A2 (fr) 2006-11-21 2008-11-20 The Regents Of The University Of Californina Anticorps de la famille anti-egfr, anticorps de la famille anti-egfr bispécifiques et leurs procédés d'utilisation
SG178789A1 (en) 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
EP2626372B1 (fr) 2007-03-29 2018-03-21 Genmab A/S Anticorps bispécifiques et procédés de production de ceux-ci
PL2155788T3 (pl) 2007-04-03 2013-02-28 Amgen Res Munich Gmbh Swoiste międzygatunkowe bispecyficzne czynniki wiążące
US7705103B2 (en) 2007-06-22 2010-04-27 3M Innovative Properties Company Polydiorganosiloxane polyoxamide copolymers
PL2173379T3 (pl) 2007-07-02 2016-02-29 Oncomed Pharm Inc Kompozycje oraz sposoby leczenia i diagnozowania nowotworu
WO2009051974A1 (fr) 2007-10-17 2009-04-23 Nuvelo, Inc. Anticorps anti-cll-1
CA2711843C (fr) 2007-12-20 2018-11-13 Laboratory Corporation Of America Holdings Procedes de diagnostic du her-2
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
HUE028536T2 (en) 2008-01-07 2016-12-28 Amgen Inc Method for producing antibody to FC heterodimer molecules using electrostatic control effects
WO2009098596A2 (fr) 2008-02-05 2009-08-13 Zymeworks Inc. Procédés de détermination de résidus corrélés dans une protéine ou autre biopolymère mettant en œuvre la dynamique moléculaire
ES2906344T3 (es) 2008-06-27 2022-04-18 Merus Nv Animal murino transgénico productor de anticuerpos
RU2540146C2 (ru) 2008-08-29 2015-02-10 Симфоген А/С Композиции рекомбинантных антител против рецептора эпидермального фактора роста
KR20110112301A (ko) 2008-11-18 2011-10-12 메리맥 파마슈티컬즈, 인크. 인간 혈청 알부민 링커 및 그 콘쥬게이트
CA2749846C (fr) 2009-01-15 2018-08-07 Laboratory Corporation Of America Holdings Procedes permettant de determiner la reponse d'un patient par mesure de her-3
CN104262483A (zh) 2009-01-26 2015-01-07 根马布股份公司 用于生成抗体混合物的方法
RU2504553C2 (ru) 2009-03-20 2014-01-20 Дженентек, Инк. Антитела к her
EP2424567B1 (fr) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Procédé de fabrication de molécules hétéromultimères
EP3916011A1 (fr) 2009-06-26 2021-12-01 Regeneron Pharmaceuticals, Inc. Anticorps bispécifiques facilement isolés avec un format natif d'immunoglobuline
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
BR112012003809A2 (pt) 2009-08-21 2019-09-24 Merrimack Pharmaceuticals Inc anticorpa monoclonal isolado ou porção de ligação a antígeno do mesmo, composição e, método para tratar câncer em um indivíduo.
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011056124A1 (fr) 2009-11-04 2011-05-12 Affibody Ab Polypeptides de liaison de her3
RU2724663C2 (ru) 2010-02-08 2020-06-25 Ридженерон Фармасьютикалз, Инк. Мышь с общей легкой цепью
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
JP6022444B2 (ja) 2010-05-14 2016-11-09 ライナット ニューロサイエンス コーポレイション ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法
MX338953B (es) 2010-08-16 2016-05-06 Novimmune Sa Metodos para la generacion de anticuerpos multiespecificos y multivalentes.
BR112013004012B1 (pt) 2010-08-20 2021-03-23 Novartis Ag Anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo ao receptor her3, seu uso e composição farmacêutica
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
RS59589B1 (sr) 2010-11-05 2019-12-31 Zymeworks Inc Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
WO2012116317A2 (fr) 2011-02-24 2012-08-30 Merrimack Pharmaceuticals, Inc. Polythérapies comprenant des agents anti-erbb3
MX2013010444A (es) 2011-03-15 2014-03-21 Merrimack Pharmaceuticals Inc Superar la resistencia a inhibidores de la via erbb.
CN107840894A (zh) 2011-03-25 2018-03-27 格兰马克药品股份有限公司 异二聚体免疫球蛋白
GB201106395D0 (en) * 2011-04-14 2011-06-01 Hubrecht Inst Compounds
NO2707391T3 (fr) 2011-05-13 2018-04-07
WO2012176779A1 (fr) 2011-06-20 2012-12-27 協和発酵キリン株式会社 Anticorps anti-erbb3
WO2013012747A1 (fr) * 2011-07-15 2013-01-24 Oncomed Pharmaceuticals, Inc. Agents de fixation aux protéines rspo et leurs utilisations
US9567827B2 (en) 2013-07-15 2017-02-14 Downhole Technology, Llc Downhole tool and method of use
CA2791109C (fr) 2011-09-26 2021-02-16 Merus B.V. Generation de molecules de liaison
KR20140069331A (ko) 2011-09-30 2014-06-09 리제너론 파아마슈티컬스, 인크. 항-ＥｒｂＢ3 항체 및 이의 용도
KR102080535B1 (ko) 2011-11-23 2020-02-24 메디뮨 엘엘씨 Her3에 특이적인 결합 분자 및 이의 용도
TW201331225A (zh) 2011-12-05 2013-08-01 Novartis Ag 針對表皮生長因子受體３（ｈｅｒ３）之域ｉｉｉ及域ｉｖ之ｈｅｒ３抗體
EP3590538A1 (fr) 2011-12-05 2020-01-08 Novartis AG Anticorps dirigés contre le récepteur 3 du facteur de croissance épidermique (her3)
CN102448183A (zh) 2012-01-18 2012-05-09 大唐移动通信设备有限公司 一种Uu接口重配置方法及设备
JP6231503B2 (ja) 2012-03-09 2017-11-15 プロメガ コーポレイションＰｒｏｍｅｇａ Ｃｏｒｐｏｒａｔｉｏｎ ｐＨセンサー
BR112014024017A8 (pt) 2012-03-27 2017-07-25 Genentech Inc Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
AU2013249985B2 (en) 2012-04-20 2017-11-23 Merus N.V. Methods and means for the production of Ig-like molecules
TW201843172A (zh) 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
ES2692951T3 (es) 2012-09-27 2018-12-05 Merus N.V. Anticuerpos IgG biespecíficos como acopladores de células T
WO2014060365A1 (fr) 2012-10-15 2014-04-24 Universität Zürich Prorektorat Mnw Ligands her2 bispécifiques pour la thérapie du cancer
CA3182876A1 (fr) 2012-11-21 2014-05-30 Janssen Biotech, Inc. Anticorps egfr/c-met bispecifiques
WO2014121196A1 (fr) 2013-02-04 2014-08-07 Oncomed Pharmaceuticals, Inc. Méthodes et surveillance de traitement par un inhibiteur de la voie wnt
MX2015011518A (es) * 2013-03-14 2016-02-03 Oncomed Pharm Inc Agentes de enlace de met y usos de los mismos.
JP6402173B2 (ja) 2013-04-05 2018-10-10 ラボラトリー コーポレイション オブ アメリカ ホールディングス Ｈｅｒ３の検出に基づく癌の診断、予後予測、および処置を容易にするためのシステムおよび方法
US10239951B2 (en) 2013-05-08 2019-03-26 Zymeworks Inc. Bispecific HER2 and HER3 antigen binding constructs
US9879081B2 (en) 2013-06-25 2018-01-30 Samsung Electronics Co., Ltd. Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
US9551208B2 (en) 2013-08-26 2017-01-24 Halliburton Energy Services, Inc. Identifying uncertainty associated with a stimulated reservoir volume (SRV) calculation
US10519247B2 (en) 2013-11-01 2019-12-31 Board Of Regents,The University Of Texas System Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
KR20240042540A (ko) 2014-02-28 2024-04-02 메뤼스 엔.페. ErbB-2와 ErbB-3에 결합하는 항체
JP6771385B2 (ja) 2014-02-28 2020-10-21 メルス ナムローゼ フェンノートシャップ 二重特異性抗体および医薬組成物
RS59077B1 (sr) * 2014-03-11 2019-09-30 Regeneron Pharma Anti-egfrviii antitela i njihova primena
MX2016012873A (es) 2014-04-04 2017-03-07 Bionomics Inc Anticuerpos humanizados que se unen al receptor 5 acoplado a proteina g que contiene repeticion rica en leucina (lgr5).
MA41123A (fr) 2014-12-02 2017-10-10 Oncomed Pharm Inc Polythérapie pour le traitement du cancer
US10383945B2 (en) * 2015-02-18 2019-08-20 The United States of America as Represented by the Department of Verterans Affairs Methods for DNA-dependent targeting of a cell permeant antibody
CA2991880A1 (fr) 2015-07-10 2017-01-19 Merus N.V. Anticorps se liant a un cd3 humain
SI3365373T1 (sl) 2015-10-23 2021-08-31 Merus N.V. Vezne molekule, ki zaviranjo rast raka
EP3393494A1 (fr) * 2015-12-22 2018-10-31 Novartis Ag Méthodes de traitement ou d'amélioration de troubles métaboliques à l'aide du facteur-15 de croissance et de différenciation (gdf-15)
CA3058341A1 (fr) 2017-03-31 2018-10-04 Merus N.V. Anticorps pour le traitement de tumeurs positives erbb-2/erbb-3
MX2019011660A (es) 2017-03-31 2019-11-18 Merus Nv Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1).
CN111148764A (zh) 2017-05-17 2020-05-12 美勒斯公司 用于乳腺癌的ErbB-2/ErbB-3双特异性抗体与内分泌治疗的组合
KR20200042485A (ko) 2017-08-09 2020-04-23 메뤼스 엔.페. EGFR 및 cMET에 결합하는 항체
KR20210121045A (ko) * 2018-12-27 2021-10-07 기가젠, 인코포레이티드 항-ctla-4 결합 단백질 및 이의 사용 방법

Also Published As

Publication number Publication date
AU2023222928A1 (en) 2023-09-21
AU2016340764B2 (en) 2023-06-01
ES2865482T3 (es) 2021-10-15
RS61800B1 (sr) 2021-06-30
CY1124108T1 (el) 2022-05-27
HUE055222T2 (hu) 2021-11-29
US20180312604A1 (en) 2018-11-01
MX2018004988A (es) 2018-11-09
EA201890866A1 (ru) 2018-09-28
JP7296728B2 (ja) 2023-06-23
EP3365373A2 (fr) 2018-08-29
KR20180100305A (ko) 2018-09-10
US11939394B2 (en) 2024-03-26
EP3912998A3 (fr) 2022-02-23
JP2019500405A (ja) 2019-01-10
SI3365373T1 (sl) 2021-08-31
MA45517A (fr) 2018-08-29
DK3365373T3 (da) 2021-04-06
CN108602888A (zh) 2018-09-28
CN115925944A (zh) 2023-04-07
PL3365373T3 (pl) 2021-08-23
CN108602888B (zh) 2022-10-04
HK1253914A1 (zh) 2019-07-05
HRP20210483T1 (hr) 2021-07-09
SG11201803359VA (en) 2018-05-30
ZA201802758B (en) 2020-08-26
US20240343824A1 (en) 2024-10-17
BR112018008068A2 (pt) 2018-11-13
EP3365373B1 (fr) 2021-03-10
NZ742290A (en) 2019-11-29
JP2024023445A (ja) 2024-02-21
CA3002957A1 (fr) 2017-04-27
MA54760A (fr) 2022-04-13
MD3365373T2 (ro) 2021-08-31
MX2022000302A (es) 2022-02-03
WO2017069628A9 (fr) 2017-10-26
JP2023008754A (ja) 2023-01-19
WO2017069628A2 (fr) 2017-04-27
EP3912998A2 (fr) 2021-11-24
AU2016340764A1 (en) 2018-05-17
LT3365373T (lt) 2021-05-25
WO2017069628A3 (fr) 2017-09-08

Similar Documents

Publication Publication Date Title
MA45517B1 (fr) Molécules de liaison inhibant la croissance de cancer
CU24058B1 (es) Antagonistas de pcsk9
WO2011038301A3 (fr) Procédés de criblage
MA42530B1 (fr) Constructions d'anticorps bispécifiques se liant à dll3 et à cd3
EA201891066A1 (ru) Антитела к ror1
EA201170030A1 (ru) Il-6-опосредованная иммунотерапия
ECSP099027A (es) Anticuerpos anti-dll4 y métodos que los usan
PA8807601A1 (es) Moleculas de union al receptor ox40 humano
CR20110035A (es) Composiciones y Métodos para Anticuerpos que se dirigen a la Proteína de Complemento C5
CR11691A (es) Anticuerpos monoclonales contra la proteína rgm a y sus usos
MA38498B1 (fr) Protéines de liaison anti-lag-3
ATE437370T1 (de) Pharmakodynamische tests mit durchflusszytometrie
CL2012003245A1 (es) Proteína de unión a antígeno aislada que se une a linfopoyetina estromal tímica (tslp); composición que comprende una proteína de unión a antígeno que une tslp correspondiente a un anticuerpo humano anti-tslp.
EA201070270A1 (ru) Пептиды с пониженным уровнем образования димеров
CO6450665A2 (es) Anticuerpos anti-fgfr3 y métodos que los utilizan
CO6721041A2 (es) Anticuerpo anti-pcsk9 y métodos de uso
MY156315A (en) Anti-vegf antibodies
MX2010004726A (es) Antigeno asociado con artritis reumatoide.
CR10069A (es) Anticuerpos anti-ox40l y métodos que los utilizan referencia cruzada con solicitudes relacionadas
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
ECSP099392A (es) Anticuerpos agonistas trkb y usos de estos
MX2010004615A (es) Anticuerpos monoclonales contra proteina c. activada e inactivada.
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
AR059096A1 (es) Anticuerpos anti- efrina -b2 y metodos que usan estos
MX2007013108A (es) Reactivos que enlazan ccx-ckr2.